Posts Tagged: Ontario Centres of Excellence (OCE)

Slyce acquires YorkU computer vision technology for retail e-commerce

Deal led by MaRS Innovation and Innovation York to strengthen Slyce’s mobile image recognition application for retail e-commerce TORONTO, Feb. 4, 2014—Slyce today announced that it has acquired a computer vision technology developed at York University that quickly analyzes and aggregates similar images. Through the acquisition, Slyce also hired former York PhD student, Dr. Ehsan Fazl-Ersi, to lead the integration of the intellectual property into Slyce’s Visual Search Platform as their new head of Research & Development. Slyce is a premium provider of visual ... Read more

Xagenic founder Shana Kelley’s MRI blog post on bringing research to market

U of T professor shares tips to her team's commercialization success When it comes to bringing research from the lab to the market, the University of Toronto’s Dr. Shana Kelley knows firsthand what it takes. She’s co-founder of Xagenic, a MaRS Innovation and U of T start-up company that’s developed the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on her research with fellow U of T colleague Professor Edward Sargent. Xagenic recently announced a Series B financing announcement following their successful $10 million ... Read more

Lang & O’Leary Exchange features Granata Decision Systems

UTEST company makes cameo through launch of OneEleven, Toronto's new data-driven accelerator for entrepreneurs CBC's Lang & O'Leary Exchange featured Granata Decision Systems, one of the first UTEST companies incubated through that program for early-stage technologies by MaRS Innovation and the University of Toronto, in their program on Wednesday, November 28, 2013. The data-driven company is one of eight to join the inaugural cohort for OneEleven, a new accelerator funded by OMERS Ventures, the Ontario Centres of Excellence, Ryerson University and other industry ... Read more

Cellax profiled in SciBX; MaRS Innovation’s MSc PoP program cited in National Post supplement

The Cellax technology was profiled in a recent issue of  SciBX (subscription necessary). MaRS Innovation is mentioned in the article as the technology's commercialization agent. Here's an excerpt: "Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that outperform Abraxane in mouse models of breast cancer. The Ontario Institute for Cancer Research (OICR) is backing the program with $1.5 million to take it to the clinic. The expectation is that the product’s ability to target the tumor stroma rather than the ... Read more

Call for Applications: MaRS Innovation seeks applicants for early-stage MSc POP projects

MaRS Innovation (MI) seeks applicants for the Medical Sciences Proof-of-Principle (MSc PoP) program, which supports early-stage medical science technologies and allows their founding teams to conduct crucial proof-of-principle work. Through the two-year MSc POP program, MI will distribute funding awards to qualified applicants within its membership on behalf of the Ministry of Research and Innovation (MRI). Funds are available in $25,000 or $75,000 grants. “At MaRS Innovation, the PoP program functions as a kind of internal Dragons' Den,” says Dr. Raphael Hofstein, president ... Read more

Dr. Raphael Hofstein’s MRI blog post: How Team Ontario’s biotechnology takes on the world

Dr. Raphael (Rafi) Hofstein is president and CEO of MaRS Innovation (MI) – the commercialization agent for an exceptional research discovery pipeline stemming from 16 leading Ontario academic institutions. As a single entry point to annual member research and development activity of $1B, MI provides a gateway for investors and licensees who wish to access Ontario’s technology assets. During the 2012 BIO convention in Boston, Dr. Hofstein blogged about how CQDM of Montreal and MaRS Innovation of Toronto had teamed up to ... Read more

Crowdmark to save teacher marking time and government dollars

Ed-tech start-up completes successful EQAO and Canadian Open Math Challenge pilots TORONTO, Canada (June 11, 2013) — Crowdmark Inc., a Canadian education technology start-up, is positioned to save cash-strapped Departments of Education millions by making massive-scale testing more efficient. Crowdmark has raised $600,000 in seed funding through the University of Toronto Early-Stage Technology (UTEST) program, MaRS Innovation and U of T’s Connaught Fund, among others. This story was covered by Yonge Street Media, TechVibes, EdSurge and PEHub. The Crowdmark assessment interface, informed by decades ... Read more

Canadian biotech sector makes strong showing at BIO2013

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013. The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ... Read more

MaRS Innovation announces new strategic partnership with Pfizer

TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics. Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals. “There’s growing consensus that transferring technologies from the university lab ... Read more

ScarX Therapeutics featured on cover of Bioworld Today

"More than 240 million surgeries are performed worldwide each year, yet there is no approved product on the market to prevent the dermal scarring that can frequently occur," writes Jennifer Boggs, managing editor of BioWorld Today in her cover story on ScarX Therapeutics. The article, "ScarX Finds New Uses for Old Drug in Dermal Scarring," appeared in the New Co section and focuses on the MaRS Innovation-Hospital for Sick Children start-up company. Here's an excerpt: "ScarX Therapeutics, a 2012 Toronto-based start-up, is looking to ... Read more
Page 3 of 512345